Eli Lilly Olumiant Alopecia Areata Treatment Approved by FDA for Pediatric Patients 12 and Older

Eli Lilly and Company News

Lilly Olumiant Alopecia Areata has received FDA approval for pediatric patients 12 and older, expanding treatment access based on Phase 3 BRAVE-AA-PEDS trial results showing substantial scalp hair regrowth in adolescents with severe alopecia areata.